A new method for delivering insulin using light-activated materials
Continuously Variable Protein Delivery Using a Photoactivated Depot
This study is testing a new way to deliver insulin for people with diabetes using a special light-activated system that releases insulin when exposed to light, making it easier and less invasive than traditional insulin pumps.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri Kansas City NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10606514 on NIH RePORTER |
What this research studies
This research focuses on developing a novel method for delivering insulin through a photoactivated depot (PAD) that allows for continuous and variable insulin release. Instead of using traditional insulin pumps that require physical connections and can lead to complications, this approach involves injecting insulin-containing materials into the skin that remain inactive until activated by an external light source. When illuminated, the materials release insulin in proportion to the light intensity, potentially providing a more reliable and less invasive method for managing blood glucose levels in diabetic patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetes who require insulin therapy.
Not a fit: Patients who do not require insulin or have other forms of diabetes management may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and convenient way for patients with diabetes to manage their insulin delivery.
How similar studies have performed: While the concept of photoactivated drug delivery is innovative, similar approaches have shown promise in other therapeutic areas, suggesting potential for success in this application.
Where this research is happening
Kansas City, United States
- University of Missouri Kansas City — Kansas City, United States (Active)
Researchers
- Principal investigator: Friedman, Simon H — University of Missouri Kansas City
- Study coordinator: Friedman, Simon H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.